ArticleESMO open2026

Atezolizumab plus pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer: final results of the phase III IMpassion050 trial.

J Huober et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.